Detecting Off-Target Bromethalin Poisoning
Researchers from the California Animal Health and Food Safety Laboratory at the University of California Davis in the USA have developed an ultrahigh-performance liquid chromatography–mass spectrometry (UHPLC–MS) method for the detection of desmethylbromethalin (DMB) residues in animal tissues.
Photo Credit: Niccirf/Getty Images
Researchers from the California Animal Health and Food Safety Laboratory at the University of California Davis in the USA have developed an ultrahigh-performance liquid chromatography–mass spectrometry (UHPLC–MS) method for the detection of desmethylbromethalin (DMB) residues in animal tissues.1 DMB is the toxic metabolite of bromethalin, a neurotoxic rodenticide that has increased in usage because of new regulations introduced by the U.S. Environmental Protection Agency (EPA) to phase out the use of other “second-generation” or long-acting anticoagulents in rodenticides intended for use in residential areas, leading consumers to look for alternatives.
The U.S. EPA introduced regulations in 2008 to phase out the use of anticoagulents in rodent poisons because of risks to children, pets, and wildlife. However, lead author Michael S. Filigenzi told The Column that consumers have now increased their use of an alternative chemical, bromethalin, increasing the danger of poisoning non-target animals. Toxicologists therefore needed a method to detect bromethalin in brain, liver, and fat tissue to confirm bromethalin exposure in animals post-mortem.
The team initially developed the UHPLC–MS–MS method with electrospray ionization using a bromethalin standard, but found the primary ion signal was not as expected. Filigenzi told The Column: “The results were consistent on different instrumentation and over time, so we developed HPLC conditions and an extraction method which appeared to give us a reasonable detection limit (in the low to mid part per billion range) and we detected it in a tissue sample from an animal suspected to have been exposed to bromethalin.” He added: “We felt that we had a useful method but our inability to determine exactly what we were detecting was worrisome, to say the least. Then, a desmethylbromethalin standard became commercially available. When we analyzed that standard, it became evident that the compound we had been detecting all along was actually the desmethylbromethalin - we weren’t detecting bromethalin at all.”
Simultaneous analysis by HPLC with UV and MS of the bromethalin standard detected a low level impurity of desmethylbromethalin (<1%), which Filigenzi attributes to the poor ionization of bromethalin by electrospray LC–MS; DMB ionizes exceedingly well. Feligenzi concluded: “Fortunately, bromethalin is metabolized to desmethylbromethalin, which is the toxic form of the compound and which will be present in animals exposed to bromethalin. This makes it a good indicator of exposure. The published method detects less than 1 ppb of desmethylbromethalin in tissue samples, which has proven to be sufficient to demonstrate exposure to the rodenticide in a number of cases.” - B.D.
Reference
1. M.S. Filingenzi, A.C. Bautista, L.S. Aston, and R.H. Poppenga, Journal of Agricultral and Food Chemistry DOI: 10.1021/jf5052706 (2015).
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
